Fig 2: Variations in serum TNF-α and IL-6 in the three groups of children. ELISA results indicate that the serum IL-6 and TNF-α in the observation group is obviously higher than that of the normal control group (P<0.05), with decreasing tendency. At 3 and 7 days after treatment, the serum IL-6 and TNF-α in the high 25-(OH)D group are lower than those in the low 25-(OH)D group. Compared with that in the control group, **P<0.01; ***P<0.001. Compared with that in the low 25-(OH)D group, #P<0.05. TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; 25-(OH)D, 25-hydroxyvitamin D; ELISA, enzyme-linked immunosorbent assay.

Fig 3: miR-155-5p promoted immune escape of colon cancer by downregulating the expression of ZC3H12B in vitroSW48 cells were transfected with oe-NC, miR-155-5p mimic + oe-NC, oe-ZC3H12B, or miR-155-5p mimic + oe-ZC3H12B. (A) qRT-PCR examining the expression patterns of miR-155-5p expression and ZC3H12B mRNA in SW48 cells. (B) Western blot analysis examining the protein expression patterns of ZC3H12B and IL-6 in SW48 cells. (C) ELISA examining the expression patterns of IL-6 in the supernatant of SW48 cells. (D) Flow cytometry examining the proliferation of T cells and the proportion of activated INF-γ+ T cells after coculture of SW48 cells with different transfections. (E) qRT-PCR examining the expression patterns of miR-155-5p and ZC3H12B mRNA in SW48 cells after coculture with exo-miR-155-5p inhibitor (SW48 cells were treated with PBS as control, the same as below). (F) Western blot analysis examining the expression patterns of ZC3H12B and IL-6 protein in SW48 cells after coculture with exo-miR-155-5p inhibitor. (G) ELISA examining the expression patterns of IL-6 in the supernatant of SW48 cells after coculture with exo-miR-155-5p inhibitor. (H) Flow cytometry examining the proliferation of T cells and the proportion of activated IFN-γ+ T cells after coculture with exo-miR-155-5p inhibitor-treated SW48 cells. The data are measurement data expressed as mean ± standard deviation. Comparisons between two groups were analyzed by independent-sample t test. Comparisons among multiple groups were analyzed by one-way ANOVA, followed by Tukey’s post hoc test. ∗p < 0.05. The cell experiment was repeated three times.

Fig 4: Hsa_circ_0010957 depletion blocks IL-6 induced activation of STAT3 signaling. (A) STAT3 and phosphorylated STAT3 protein levels when CD4+ T cells were treated with IL-6 and transfected with hsa_circ_0010957 siRNA and miR-125b inhibitor. (B-D) IL-18, IL-6 and IL-17 levels detected in cell supernatant when CD4+ T cells were treated with IL-6 and transfected with hsa_circ_0010957 siRNA and miR-125b inhibitor. Data are shown as mean ± SD *P<0.05. NS, no significance; IL, interleukin; miR, microRNA; siRNA, small interfering RNA; NC, negative control.

Fig 5: (A) Difference between physical activity frailty criteria and (B) IL-6 (pg/mL) and weight loss frailty criteria and IL-6 (pg/mL).